ADIL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Adial Pharmaceuticals Inc (ADIL) is not a good buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is showing bearish technical indicators, lacks positive catalysts, and has weak financial performance. Additionally, there are no strong trading signals or recent news to support a buy decision.
The stock is in a bearish trend with moving averages indicating downward momentum (SMA_200 > SMA_20 > SMA_5). The RSI is at 10.424, signaling an oversold condition, but this alone is not enough to justify a buy. The MACD is slightly positive but contracting, showing weak momentum. Key support levels are at 1.99 and 1.776, with resistance at 2.338 and 2.686.
NULL. There are no recent news updates or significant positive developments. Analysts remain cautiously optimistic about the AUD opportunity and regulatory environment but have significantly lowered the price target.
The stock has experienced a reverse split and is expected to face dilution. Financial performance is weak, with a significant net income loss and zero revenue growth. The stock has bearish technical indicators and lacks trading momentum.
In Q4 2025, revenue remained at 0 with no YoY growth. Net income dropped to -1,996,163, down -3.60% YoY. EPS improved significantly to -298.27, up 3596.03% YoY, but this is due to adjustments rather than operational improvements. Gross margin remained at 0.
Maxim recently lowered the price target from $37.50 to $8 while maintaining a Buy rating. The adjustment reflects the reverse split and expected dilution, though the analyst remains positive on the AUD opportunity and regulatory environment.
